BBOT
BRIDGEBIO ONCOLOGY THERAPEUT
Latest close $8.96 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 2 of 2 parsed filing(s)| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Associates CIK0000080255 | Sep 30, 2025 observed Nov 14, 2025 filed · 45d Initial Schedule 13G | Initial Schedule 13G | 885.0K -242.6K | 12.00% +6.00 pts | $11.58 | $13.12 | $8.96 |
| T. Rowe Price Associates CIK0000080255 | Sep 30, 2024 observed Nov 14, 2024 filed · 45d Initial Schedule 13G | Initial Schedule 13G | 1.1M | 6.00% | $8.96 |